Princeton Capital Management LLC bought a new position in shares of Gilead Sciences (NASDAQ:GILD) during the 4th quarter, HoldingsChannel reports. The firm bought 5,302 shares of the biopharmaceutical company’s stock, valued at approximately $380,000.
Other large investors also recently bought and sold shares of the company. BancorpSouth Bank bought a new position in shares of Gilead Sciences in the fourth quarter worth $3,298,000. CT Mason bought a new position in shares of Gilead Sciences in the fourth quarter worth $3,809,000. Oak Grove Capital LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth $2,040,000. Cornerstone Capital Inc. increased its holdings in shares of Gilead Sciences by 22.9% in the fourth quarter. Cornerstone Capital Inc. now owns 62,966 shares of the biopharmaceutical company’s stock worth $4,511,000 after purchasing an additional 11,730 shares during the period. Finally, ARK Investment Management LLC increased its holdings in shares of Gilead Sciences by 275.5% in the fourth quarter. ARK Investment Management LLC now owns 23,674 shares of the biopharmaceutical company’s stock worth $1,696,000 after purchasing an additional 17,369 shares during the period. Hedge funds and other institutional investors own 77.91% of the company’s stock.
Shares of NASDAQ:GILD opened at $73.41 on Friday. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54. The stock has a market cap of $97,554.05, a PE ratio of 8.58, a P/E/G ratio of -1.72 and a beta of 1.19. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same period last year, the firm earned $2.70 earnings per share. The company’s revenue for the quarter was down 18.7% compared to the same quarter last year. analysts anticipate that Gilead Sciences will post 6.21 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were paid a dividend of $0.57 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date was Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
Several research analysts have recently weighed in on GILD shares. Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. Finally, Wells Fargo raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $79.02 to $96.00 in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $88.61.
In other news, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the transaction, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John Francis Cogan sold 5,833 shares of the firm’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $80.93, for a total value of $472,064.69. The disclosure for this sale can be found here. Insiders have sold 426,934 shares of company stock worth $33,847,101 over the last ninety days. Insiders own 1.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “5,302 Shares in Gilead Sciences (GILD) Acquired by Princeton Capital Management LLC” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/5302-shares-in-gilead-sciences-gild-acquired-by-princeton-capital-management-llc.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.